This Study Will Compare the Effect of Starch Containing to Non-Starch Containing Intravenous Fluid on Blood Loss During Coronary Artery Bypass Graft Surgery

Inclusion Criteria: * Male or female, 18 - 85 years of age, inclusive * Willing and able to provide informed consent * Elective primary coronary artery bypass graft (CABG) requiring cardiopulmonary bypass, isolated valve repair, or isolated valve replacement surgery, or combined single valve plus CABG. Exclusion Criteria: * Emergency surgery (\< 12 hours from determination of need for surgery) * Significant other concomitant surgery (including, but not limited to, multiple valve replacement, CEA, planned circulatory arrest, etc.) * LVEF \< 25 % * Preoperative use of inotropes * Preoperative intraoartic balloon pump (IABP) * Renal dysfunction: Serum Creatinine \>140 μmol/L * Hepatic dysfunction: AST or ALT \> 2.5 x upper limit normal; or otherwise known hepatic disease * Preoperative Hb \< 100 g/L * Platelet count \<100,000/mm3, * INR \> 1.3; PTT \> 38 sec (with the exception of patients receiving preoperative heparin) * History or family history of bleeding disorder * Patients currently receiving: Eptifibatide (Integrilin) within 12 hours Danaparoid, Enoxaparin sodium (Lovenox) or other low molecular weight heparin within 24 hours ,Clopidogrel (Plavix) within 7 days ,Warfarin (Coumadin) within 5 days, Ticlopidine (Ticlid) within 7 day * Dermatological syndromes with pruritus * Planned neuraxial anesthetic technique * Receipt of an investigational drug or device, within 30 days prior to study treatment * Pregnant or breast feeding females